Prostate Cancer Imaging Therapeutics
1. Pylarify patent expiration
Treatment: Method of positron emission tomography (pet) in men with prostate cancer
PYLARIFY's oppositions filed in EPO
Can you believe PYLARIFY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11851407 | PROGENICS PHARMS INC | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPYL |
Jun, 2037
(11 years from now) | |
| US8778305 | PROGENICS PHARMS INC | PSMA-binding agents and uses thereof |
Sep, 2030
(4 years from now) | |
| US9861713 | PROGENICS PHARMS INC | PSMA-binding agents and uses thereof |
Jul, 2029
(3 years from now) | |
| US10947197 | PROGENICS PHARMS INC | Synthesis of the radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [18F]DCFPyL |
Jun, 2037
(11 years from now) | |
| US12070513 | PROGENICS PHARMS INC | PSMA-binding agents and uses thereof |
Jul, 2029
(3 years from now) | |
| US8487129 | PROGENICS PHARMS INC | Heterodimers of glutamic acid |
Nov, 2027
(1 year, 9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 26, 2026 |
Drugs and Companies using PIFLUFOLASTAT F-18 ingredient
NCE-1 date: 26 May, 2025
Market Authorisation Date: 26 May, 2021
Dosage: SOLUTION
More Information on Dosage
PYLARIFY family patents
